[go: up one dir, main page]

BRPI0014428B8 - composto, composição farmacêutica, e, uso de um composto para o tratamento ou prevenção da doença infecciosa do hiv - Google Patents

composto, composição farmacêutica, e, uso de um composto para o tratamento ou prevenção da doença infecciosa do hiv

Info

Publication number
BRPI0014428B8
BRPI0014428B8 BRPI0014428A BR0014428A BRPI0014428B8 BR PI0014428 B8 BRPI0014428 B8 BR PI0014428B8 BR PI0014428 A BRPI0014428 A BR PI0014428A BR 0014428 A BR0014428 A BR 0014428A BR PI0014428 B8 BRPI0014428 B8 BR PI0014428B8
Authority
BR
Brazil
Prior art keywords
substituted
compound
group
bond
heterocyclic group
Prior art date
Application number
BRPI0014428A
Other languages
English (en)
Other versions
BRPI0014428B1 (pt
BR0014428A (pt
Inventor
Baba Masanori
Kanzaki Naoyuki
Nishimura Osamu
Imamura Shinichi
Hashiguchi Shohei
Hattori Taeko
Sugihara Yoshihiro
Original Assignee
Takeda Chemical Industries Ltd
Tobira Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26554466&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0014428(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd, Tobira Therapeutics Inc filed Critical Takeda Chemical Industries Ltd
Publication of BR0014428A publication Critical patent/BR0014428A/pt
Publication of BRPI0014428B1 publication Critical patent/BRPI0014428B1/pt
Publication of BRPI0014428B8 publication Critical patent/BRPI0014428B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • AIDS & HIV (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

"composto, pró medicamento de um composto, composição farmacêutica, uso de um composto, e, métodos para antagonizar ccr5, e, para produzir um composto". um composto da fórmula (i) (em que r^ 1^ é um átomo de hidrogênio, um grupo hidrocarboneto que pode ser substituído, um grupo heterocíclico não aromático que pode ser substituído, r^ 2^ é um grupo hidrocarboneto que pode ser substituído, um grupo heterocíclico não aromático que pode ser substituído ou r^ 1^ e r^ 2^ podem combinar um com o outro juntos com a para formar um grupo heterocíclico que pode ser substituído; a é n ou n^ +^-r^ 5^<sym>-y^ -^(r^ 5^ é um grupo hidrocarboneto; y^ -^ é um contra ânion); r^ 3^ é um grupo hidrocarboneto cíclico que pode ser substituído ou um grupo heterocíclico que pode ser substituído; n é 0 ou 1; r^ 4^ é um átomo de hidrogênio, um grupo hidrocarboneto que pode ser substituído, um grupo heterocíclico que pode ser substituído, um grupo alcóxi que pode ser substituído, um grupo arilóxi que pode ser substituído ou um grupo amino que pode ser substituído, e é um grupo hidrocarboneto alifático bivalente que pode ser substituído por grupo(s) outros que não oxo; g^ 1^ é uma ligação, co ou so~ 2~; g^ 2^ é co, so~ 2~, nhco, conh ou oco; j é metina ou um átomo de nitrogênio; e cada um de q e r é uma ligação ou um hidrocarboneto alifático bivalente c~ 1-3~ que pode ser substituído; contanto que j seja metina quando g^ 2^ é oco, que um de q e r não seja uma ligação quando o outro é uma ligação e que cada um de q e r não seja substituído por grupo(s) oxo quando g^ 1^ é uma ligação) ou um sal deste têm uma atividade antagonística ao ccr5 potente e podem ser vantajosamente usados para o tratamento ou a prevenção de doença infecciosa de vários hiv em seres humanos (por exemplo, a aids).
BRPI0014428A 1999-10-01 2000-09-29 composto, composição farmacêutica, e, uso de um composto para o tratamento ou prevenção da doença infecciosa do hiv BRPI0014428B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP28208899 1999-10-01
JP2000046749 2000-02-18
PCT/JP2000/006755 WO2001025200A1 (en) 1999-10-01 2000-09-29 Cyclic amine compounds as ccr5 antagonists

Publications (3)

Publication Number Publication Date
BR0014428A BR0014428A (pt) 2002-06-11
BRPI0014428B1 BRPI0014428B1 (pt) 2016-08-02
BRPI0014428B8 true BRPI0014428B8 (pt) 2021-05-25

Family

ID=26554466

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0014428A BRPI0014428B8 (pt) 1999-10-01 2000-09-29 composto, composição farmacêutica, e, uso de um composto para o tratamento ou prevenção da doença infecciosa do hiv

Country Status (22)

Country Link
US (2) US6562978B1 (pt)
EP (2) EP1220842B1 (pt)
JP (2) JP3814136B2 (pt)
KR (1) KR20020060190A (pt)
CN (1) CN1390201A (pt)
AR (1) AR025884A1 (pt)
AT (1) ATE400555T1 (pt)
AU (1) AU7448700A (pt)
BR (1) BRPI0014428B8 (pt)
CA (2) CA2608807A1 (pt)
CO (1) CO5380013A1 (pt)
CY (1) CY1108403T1 (pt)
DE (1) DE60039446D1 (pt)
DK (1) DK1220842T3 (pt)
ES (1) ES2310173T3 (pt)
HU (1) HUP0300138A3 (pt)
NO (1) NO20021450L (pt)
PE (1) PE20010628A1 (pt)
PL (1) PL203984B1 (pt)
PT (1) PT1220842E (pt)
WO (1) WO2001025200A1 (pt)
ZA (1) ZA200202593B (pt)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
GB2359078A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
GB0005642D0 (en) 2000-03-10 2000-05-03 Astrazeneca Uk Ltd Chemical compounds
AU2001288110A1 (en) * 2000-09-27 2002-04-08 Takeda Chemical Industries Ltd. Spiro compounds
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
WO2002051414A1 (en) * 2000-12-22 2002-07-04 Takeda Chemical Industries, Ltd. Medicinal compositions for oral use
CA2434934A1 (en) * 2001-01-18 2002-07-25 Takeda Chemical Industries, Ltd. Process for preparation of benzylpiperidine compounds
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
WO2002088089A1 (en) * 2001-04-19 2002-11-07 Banyu Pharmaceutical Co., Ltd. Spiropiperidine derivatives, nociceptin receptor antagonists containing the same as the active ingredient and medicinal compositions
CA2484384A1 (en) * 2002-04-19 2003-10-30 Takeda Pharmaceutical Company Limited Preventives for hiv infection
US20050245537A1 (en) * 2002-04-24 2005-11-03 Noboru Tsuchimori Use of compounds having ccr antagonism
AU2003266528A1 (en) * 2002-09-20 2004-04-08 Takeda Pharmaceutical Company Limited Cyclic amine compound, process for producing the same, and use
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
EP1553098A1 (en) * 2002-10-18 2005-07-13 Ono Pharmaceutical Co., Ltd. Spiroheterocyclic derivative compounds and drugs comprising the compounds as the active ingredient
WO2004058264A1 (en) * 2002-12-24 2004-07-15 Biofocus Plc Compound libraries of 2h-spiro (isoquinoline-1, -piperidine derivatives and related compounds for targetting compounds capable of binding to the g-protein receptor
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
US7498346B2 (en) 2003-12-11 2009-03-03 Genzyme Corporation Chemokine receptor binding compounds
EP1708703A4 (en) 2003-12-11 2008-04-09 Anormed Inc CHEMOKIN RECEPTOR BINDING COMPOUNDS
TW200630337A (en) 2004-10-14 2006-09-01 Euro Celtique Sa Piperidinyl compounds and the use thereof
SE0403084D0 (sv) 2004-12-17 2004-12-17 Astrazeneca Ab Chemical process
NZ556017A (en) * 2004-12-24 2009-10-30 Prosidion Ltd G-protein coupled receptor (gpr116) agonists and use thereof for treating obesity and diabetes
MX2007007428A (es) 2004-12-24 2007-07-16 Astrazeneca Ab Compuestos heterociclicos, antagonistas de ccr2b.
WO2006130426A2 (en) * 2005-05-27 2006-12-07 Kemia, Inc. Modulators of ccr-5 activity
AU2007221021B2 (en) 2006-02-28 2013-01-17 Dart Neuroscience (Cayman) Ltd Therapeutic piperazines as PDE4 inhibitors
AU2013200480B2 (en) * 2006-02-28 2016-06-09 Dart Neuroscience (Cayman) Ltd. Therapeutic compounds
EP1989185B8 (en) * 2006-02-28 2013-06-26 Dart NeuroScience LLC Therapeutic compounds
WO2007110449A1 (en) * 2006-03-29 2007-10-04 Euro-Celtique S.A. Benzenesulfonamide compounds and their use
TW200815353A (en) * 2006-04-13 2008-04-01 Euro Celtique Sa Benzenesulfonamide compounds and their use
TW200812963A (en) * 2006-04-13 2008-03-16 Euro Celtique Sa Benzenesulfonamide compounds and the use thereof
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2008073450A2 (en) * 2006-12-12 2008-06-19 Georgetown University Benzamide compounds
GB0625523D0 (en) * 2006-12-21 2007-01-31 Ge Healthcare Ltd In vivo imaging agents
WO2008124118A1 (en) * 2007-04-09 2008-10-16 Purdue Pharma L.P. Benzenesulfonyl compounds and the use therof
EP2182809B1 (en) 2007-08-27 2018-01-17 Dart Neuroscience (Cayman) Ltd Therapeutic isoxazole compounds
US8765736B2 (en) * 2007-09-28 2014-07-01 Purdue Pharma L.P. Benzenesulfonamide compounds and the use thereof
WO2009045382A1 (en) 2007-10-04 2009-04-09 Merck & Co., Inc. Substituted aryl sulfone derivatives as calcium channel blockers
US8772297B2 (en) * 2010-02-17 2014-07-08 Kyoto University TGF-β signal transduction inhibitor
AR080375A1 (es) 2010-03-05 2012-04-04 Sanofi Aventis Procedimiento para la preparacion de 2-(cicloheximetil)-n-{2-[(2s)-1-metilpirrolidin-2-il] etil}-1,2,3,4-tetrahidroisoquinolina- 7-sulfonamida
US20130023496A1 (en) 2010-04-02 2013-01-24 Randy Tressler Combination Therapy Comprising A CCR5 Antagonist, A HIV-1 Protease Inhibtior and a Pharmacokinetic Enhancer
CN101921224B (zh) * 2010-05-21 2012-01-18 中国人民解放军军事医学科学院生物工程研究所 1-（3-氨基丙基）哌嗪-4-氨基酰胺类化合物及其制备方法与应用
KR200453948Y1 (ko) * 2011-02-28 2011-06-09 최문희 파마로드
EP2741777B1 (en) 2011-08-12 2017-01-18 INSERM - Institut National de la Santé et de la Recherche Médicale Methods and pharmaceutical compositions for treatment of pulmonary hypertension
CN103130709B (zh) * 2011-11-22 2017-04-12 常州亚邦制药有限公司 具有抗hiv活性的3‑氨基丙酸哌啶酰胺类化合物，合成方法及用途
ES2797123T3 (es) 2011-12-21 2020-12-01 Novira Therapeutics Inc Agentes antivirales para la hepatitis B
CN104902885A (zh) 2012-08-28 2015-09-09 爱尔兰詹森科学公司 氨磺酰基-芳基酰胺和其作为药物用于治疗乙型肝炎的用途
PL2961732T3 (pl) 2013-02-28 2017-09-29 Janssen Sciences Ireland Uc Sulfamoilo-aryloamidy i ich stosowanie jako leków do leczenia wirusowego zapalenia wątroby typu B
EA027068B1 (ru) 2013-04-03 2017-06-30 Янссен Сайенсиз Айрлэнд Юси Производные n-фенилкарбоксамида и их применение в качестве лекарственных препаратов для лечения гепатита b
CN105960400B (zh) 2013-05-17 2019-05-31 爱尔兰詹森科学公司 氨磺酰基噻吩酰胺衍生物及其作为药物用于治疗乙型肝炎的用途
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
EP3357906B1 (en) 2013-07-25 2019-12-04 Janssen Sciences Ireland Unlimited Company Glyoxamide substituted pyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b
JP6452119B2 (ja) 2013-10-23 2019-01-16 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー カルボキサミド誘導体およびｂ型肝炎の処置のための医薬品としてのその使用
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US20150216938A1 (en) 2014-02-05 2015-08-06 Novira Therapeutics Inc. Combination therapy for treatment of hbv infections
HK1225389A1 (zh) 2014-02-06 2017-09-08 Janssen Sciences Ireland Uc 氨磺酰基吡咯酰胺衍生物及其作为药物用於治疗乙型肝炎的用途
EP3233077A4 (en) 2014-12-19 2018-08-08 The Broad Institute Inc. Dopamine d2 receptor ligands
US10752588B2 (en) 2014-12-19 2020-08-25 The Broad Institute, Inc. Dopamine D2 receptor ligands
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
KR20180129943A (ko) 2016-04-15 2018-12-05 노비라 테라퓨틱스, 인코포레이티드 캡시드 조립 억제제를 포함하는 배합물 및 방법
EP4092013A1 (en) 2017-06-20 2022-11-23 Imbria Pharmaceuticals, Inc. Compositions and methods for increasing efficiency of cardiac metabolism
MA52019A (fr) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Co Schéma posologique de modulateur d'assemblage de capside
US12286401B2 (en) 2018-07-31 2025-04-29 The Trustees Of The University Of Pennsylvania Small molecules that sensitize HIV-1 infected cells to antibody dependent cellular cytotoxicity
EP4497474A3 (en) 2018-10-17 2025-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
MX2021010145A (es) 2019-02-22 2021-09-14 Janssen Sciences Ireland Unlimited Co Derivados de amida utiles en el tratamiento de una infeccion por vhb o de enfermedades inducidas por vhb.
EP3966205A1 (en) 2019-05-06 2022-03-16 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of hbv infection or hbv-induced diseases
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
CN114478585A (zh) * 2020-10-26 2022-05-13 上海青煜医药科技有限公司 含氮稠杂环类化合物及其制备方法和应用
CN117098560A (zh) * 2021-04-23 2023-11-21 中国人民解放军军事科学院军事医学研究院 抗病毒多肽化合物
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine
WO2023107547A2 (en) * 2021-12-08 2023-06-15 Kineta, Inc. Azetidine and spiroazetidine compounds and uses thereof
CN119317620A (zh) 2022-06-13 2025-01-14 亚力维克希斯股份有限公司 氮杂环烷基羰基环状胺化合物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4203988A (en) * 1975-11-12 1980-05-20 Merck & Co., Inc. Pyridinyl ureas and pharmaceutical use
JPH0680054B2 (ja) * 1985-06-19 1994-10-12 吉富製薬株式会社 ピペリジン誘導体
AU688318B2 (en) * 1993-04-05 1998-03-12 Mannkind Corporation M2 receptor ligand for the treatment of neurological disorders
AU8576098A (en) 1997-07-25 1999-02-16 Merck & Co., Inc. Cyclic amine modulators of chemokine receptor activity
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
CA2319781A1 (en) 1998-02-02 1999-08-05 Liping Wang Cyclic amine modulators of chemokine receptor activity
CA2434934A1 (en) * 2001-01-18 2002-07-25 Takeda Chemical Industries, Ltd. Process for preparation of benzylpiperidine compounds

Also Published As

Publication number Publication date
AR025884A1 (es) 2002-12-18
PE20010628A1 (es) 2001-06-18
ES2310173T3 (es) 2009-01-01
ATE400555T1 (de) 2008-07-15
JP2003048880A (ja) 2003-02-21
DK1220842T3 (da) 2008-11-10
BRPI0014428B1 (pt) 2016-08-02
US20030114443A1 (en) 2003-06-19
ZA200202593B (en) 2003-04-03
CN1390201A (zh) 2003-01-08
US7348324B2 (en) 2008-03-25
NO20021450L (no) 2002-06-03
PT1220842E (pt) 2008-10-17
CA2608807A1 (en) 2001-04-12
EP1886994A1 (en) 2008-02-13
EP1220842B1 (en) 2008-07-09
BR0014428A (pt) 2002-06-11
HUP0300138A3 (en) 2003-06-30
CY1108403T1 (el) 2014-02-12
NO20021450D0 (no) 2002-03-22
HK1046905A1 (en) 2003-01-30
EP1220842A1 (en) 2002-07-10
US6562978B1 (en) 2003-05-13
JP3814136B2 (ja) 2006-08-23
DE60039446D1 (de) 2008-08-21
CA2385938C (en) 2010-02-16
CA2385938A1 (en) 2001-04-12
JP2001302633A (ja) 2001-10-31
CO5380013A1 (es) 2004-03-31
PL203984B1 (pl) 2009-11-30
AU7448700A (en) 2001-05-10
KR20020060190A (ko) 2002-07-16
PL356034A1 (en) 2004-06-14
HUP0300138A2 (en) 2003-05-28
WO2001025200A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
BRPI0014428B8 (pt) composto, composição farmacêutica, e, uso de um composto para o tratamento ou prevenção da doença infecciosa do hiv
PL398536A1 (pl) Pochodne pirazolu i kompozycje farmaceutyczne zawierające je oraz ich zastosowanie do leczenia HIV
BRPI0014526B8 (pt) compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo
HUP0300641A2 (hu) Triazaspiro[5.5]undekán-származékok és hatóanyagként ezeket tartalmazó gyógyszerkészítmények
UA72917C2 (en) Cyclic carbamates derivatives, pharmaceutical composition containing said derivatives of cyclic carbamates and active ingredients as modulators of the progesterone receptor
AR030507A1 (es) Compuesto de pirazolopiridina y los usos farmaceuticos del mismo
MXPA03008528A (es) Medicamentos que contienen derivados de triazaspiro [5.5] undecano como el ingrediente activo.
HUP0402458A2 (hu) Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek
BR9909666A (pt) Derivados de amida e antagonistas de nociceptina
CY1107532T1 (el) Παραγωγα ναφθυριδινης, παρασκευη και χρηση τους ως αναστολεις του ισοενζυμου 4 της φωσφοδιεστepασης (pde4)
ATE469136T1 (de) Inhibitoren von 11-beta- hydroxysteroiddehydrogenase typ 1
MY139243A (en) Prodrugs of piperazine and substituted piperidine antiviral agents.
HUP0302337A2 (hu) Pirimidin-2,4,6-trion metalloproteáz inhibitorok, ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk
DK2314582T3 (da) Heterocykliske forbindelser som antivirusmidler
WO2000010965A3 (en) Quaternary ammonium salts and their use as anti-hiv agents
BR0111569A (pt) Agentes antivirais de imidazopiridina e imidazopirimidina
SE0102438D0 (sv) New compounds
HUP0400365A2 (hu) 3-Fluor-pirrolidinek, mint cukorbetegség elleni szerek és a vegyületeket tartalmazó gyógyszerkészítmények
NO20045486L (no) Nye forbindelser og deres anvendelse
GEP20084284B (en) Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
BR0212069A (pt) Agentes antidiabéticos orais
KR880013937A (ko) 옥세타노신 유도체
AR029499A1 (es) Derivados de pirrolidina, farmaceuticamente activos, aplicables en el tratamiento y/o prevencion de partos y/o nacimientos prematuros y/o dismenorrea, uso de dichos derivados en la preparacion de composiciones farmaceuticas para dichos tratamientos y proceso de preparacion de los derivados mencionad
AR035196A1 (es) Derivados de guanidina o biguanidina y el uso de los mismos para la fabricacion de medicamentos antivirales y antimicrobianos
HUP0204354A2 (hu) Új heterociklusos vegyületek, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények és alkalmazásuk

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, E 7A ANUIDADES.

B08G Application fees: restoration [chapter 8.7 patent gazette]
B25A Requested transfer of rights approved

Owner name: TOBIRA THERAPEUTICS, INC. (US)

Free format text: TRANSFERIDO DE: TAKEDA CHEMICAL INDUSTRIES, LTD.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]

Free format text: DE ACORDO COM ART. 34 " II " DA LPI ( LEI 9279, DE 14/05/96 ) , O EXAME FICA SUSPENSO PARA QUE O REQUERENTE APRESENTE DOCUMENTOS NECESSARIOS A REGULARIZACAO DO PROCESSO E EXAME DO PEDIDO.

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/08/2016, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 29/09/2000 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 29/09/2020

B15V Prolongation of time limit allowed